Antithrombin III human

DB11598ApprovedInvestigationalProtein Based Therapies

Antithrombin III human is an alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency. A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes.

Mechanism
Curator reviewed
Primary indication
Antithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolismCurator reviewed · 1 structured indication
First approval
Canada, 1999 · United States, 1991
Also known as
Antithrombin III · Antithrombin III (human) · Antithrombin III (human) concentrate IV · Antithrombin III human plasma-derived · Antithrombin III, human
Code names
ORG 10849
Brand names
  • Thrombate III

Resolves to

What you can answer from here — as of November 13, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1,136Drug interactionsStructured to mechanism, not free text
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
46Marketed productsAcross 8 countries and 16 labellers
Sign in
1ATC codeIncluding every combination product, plus 21 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Antithrombin III human, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account